Onkologie. 2025:19(1):38-41 | DOI: 10.36290/xon.2025.009

Case report of a patient with a long-term effect trifludine/tipiracil

Anna Nohejlová Medková
Onkologická klinika FN v Motole a 2. lékařská fakulty UK, Praha

Colorectal cancer is among the most common malignancies in the Czech Republic. Over the past decades, significant advances in its treatment have been achieved, leading to prolonged overall survival of patients. In 2016, based on the results of the RECOURSE study, a new drug for pretreated patients - trifluridine/tipiracil (TAS-102), was approved. Compared to placebo, it prolongs overall survival without compromi­sing quality of life. We present the case of a patient who has experienced long-term benefits from this therapy.

Keywords: colorectal cancer, trifluridine, tipiracil, quality of life.

Accepted: February 27, 2025; Published: March 10, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nohejlová Medková A. Case report of a patient with a long-term effect trifludine/tipiracil. Onkologie. 2025;19(1):38-41. doi: 10.36290/xon.2025.009.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF

    References

    1. Robert JM, Van Cutsem E, Falcone A, et al. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer N Engl J Med. 2015;372:1909-1919. Go to original source... Go to PubMed...
    2. Available from: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/asd-4-zhoubny-novotvar-kolorekta-c18-20/.
    3. Yoshino T, Cleary JM, Van Cutsem E, et al. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials, Annals of Oncology. Ann Oncol. 2020;31(1):88-95. doi: 10.1016/j.annonc.2019.10.005. PMID: 31912801; PMCID: PMC7491979. Go to original source... Go to PubMed...
    4. Tabernero J, Argiles G, Sobrero AF. Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis. ESMO Open. 2020;5(4):e000752. doi: 10.1136/esmoopen-2020-000752. PMID: 32817131; PMCID: PMC7440836. Go to original source... Go to PubMed...
    5. Prager GW, Taieb J, Fakih M, et al. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer, N Engl J Med. 2023;388:1657-1667. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.